Company news

BioCryst Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

September 17, 2023

BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update

August 2, 2023

BioCryst to Report Second Quarter 2023 Financial Results on August 3

July 19, 2023

BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey

July 18, 2023

BioCryst to Participate in the 2023 US HAEA National Summit

July 16, 2023

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

May 30, 2023

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile

May 21, 2023

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023

BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)

April 26, 2023

BioCryst to Report First Quarter 2023 Financial Results on May 3

April 18, 2023

BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon

April 17, 2023

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

March 30, 2023

BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success

March 28, 2023

CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

March 7, 2023

BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)

February 23, 2023

BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

February 20, 2023

BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

February 6, 2023

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 2, 2023

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

January 25, 2023

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

January 22, 2023

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

January 8, 2023

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

January 8, 2023

BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

December 14, 2022

BioCryst to Present at JMP Securities Hematology & Oncology Summit

December 4, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health

November 27, 2022

BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

November 9, 2022

BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones

October 31, 2022

BioCryst to Report Third Quarter 2022 Financial Results on November 1

October 17, 2022

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

September 13, 2022

FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

August 30, 2022

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

August 25, 2022

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness

August 24, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia

August 17, 2022

BioCryst Resumes Enrollment in BCX9930 Clinical Program

August 3, 2022

BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones

August 3, 2022

BioCryst to Report Second Quarter 2022 Financial Results on August 4

July 20, 2022

BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

June 30, 2022

BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

June 21, 2022

BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America

June 8, 2022

FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250

June 7, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic

June 6, 2022

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

June 5, 2022

BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones

May 4, 2022

European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

April 26, 2022

BioCryst to Report First Quarter 2022 Financial Results on May 5

April 20, 2022

BioCryst Pauses Enrollment in BCX9930 Clinical Trials

April 7, 2022

BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)

February 23, 2022

BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones

February 22, 2022

BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases

February 21, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 36 decks. Every deck is listed under its year.